GRIFOLS: BROOKFIELD CONFIRMA QUE BARAJA UNA OFERTA A 10,5 EUROS/ACC. PARA SU POTENCIAL OPA SOBRE GRF (ANÁLISIS BANCO SABADELL)
El fondo Brookfield acaba de confirmar que trasladó el 11 de noviembre al Comité de Transacción de GRF que estaba considerando (como valor no vinculante) un precio de 10,5 euros/acc.Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.